Published in Cancer Res on March 01, 2004
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther (2008) 1.96
Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci U S A (2005) 1.55
Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A (2005) 1.51
Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A (2009) 1.34
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther (2010) 1.30
Thrombospondin-based antiangiogenic therapy. Microvasc Res (2007) 1.26
PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One (2007) 1.24
Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol (2009) 1.22
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther (2008) 1.19
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer (2008) 1.10
Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer (2010) 1.00
Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Curr Drug Targets (2008) 0.97
Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment. Mol Cancer Ther (2007) 0.97
Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget (2010) 0.96
Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas. Oncoimmunology (2013) 0.95
Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine. Curr Cancer Drug Targets (2009) 0.94
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer (2008) 0.92
A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. J Exp Med (2011) 0.92
Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment. Front Endocrinol (Lausanne) (2013) 0.92
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol (2013) 0.92
Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast (2009) 0.91
Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology. Neoplasia (2005) 0.90
Inhibition of tumor angiogenesis by oral etoposide. Exp Ther Med (2010) 0.88
Vasohibin: the feedback on a new inhibitor of angiogenesis. J Clin Invest (2004) 0.87
VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment. BMC Cancer (2010) 0.87
Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother (2010) 0.86
Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas. Oncol Rep (2011) 0.86
Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis. Cancer Lett (2012) 0.83
DNA Damage and Pulmonary Hypertension. Int J Mol Sci (2016) 0.81
Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol (2013) 0.81
Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer. Int J Breast Cancer (2011) 0.81
Thrombospondin-1 deficiency causes a shift from fibroproliferative to inflammatory kidney disease and delays onset of renal failure. Am J Pathol (2014) 0.79
The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts. BMC Cancer (2015) 0.78
Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth? APMIS (2013) 0.78
Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. Pharmaceuticals (Basel) (2010) 0.78
Lack of efficacy of combined antiangiogenic therapies in xenografted human melanoma. J Oncol (2011) 0.75
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Childs Nerv Syst (2015) 0.75
Role of vascular normalization in benefit from metronomic chemotherapy. Proc Natl Acad Sci U S A (2017) 0.75
Resistance to metronomic chemotherapy and ways to overcome it. Cancer Lett (2017) 0.75
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med (2007) 9.51
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003) 7.91
Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell (2005) 7.41
Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol (2008) 5.83
TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet (2005) 5.53
Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem (2007) 5.37
Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med (2010) 4.88
Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest (2004) 4.65
Origin and function of myofibroblasts in kidney fibrosis. Nat Med (2013) 4.55
Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med (2008) 3.98
Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res (2007) 3.86
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 3.74
Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell (2003) 3.68
eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol Cell (2012) 3.63
Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med (2010) 3.60
Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell (2009) 3.46
Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem (2003) 3.36
The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med (Berl) (2004) 3.32
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell (2012) 3.19
Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int (2002) 3.16
Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci U S A (2006) 3.03
The thrombospondins. Int J Biochem Cell Biol (2004) 3.01
Endogenous inhibitors of angiogenesis. Cancer Res (2005) 2.88
Loss of β1-integrin from urothelium results in overactive bladder and incontinence in mice: a mechanosensory rather than structural phenotype. FASEB J (2013) 2.86
Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol (2008) 2.85
Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell (2008) 2.78
Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem (2007) 2.67
Cancer without disease. Nature (2004) 2.65
Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest (2012) 2.58
Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development (2002) 2.57
Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med (2013) 2.55
Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci U S A (2002) 2.54
VEGFA is necessary for chondrocyte survival during bone development. Development (2004) 2.54
Biomolecular characterization and protein sequences of the Campanian hadrosaur B. canadensis. Science (2009) 2.48
Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med (2012) 2.44
Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol (2005) 2.38
NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest (2008) 2.29
Structure and function of basement membranes. Exp Biol Med (Maywood) (2007) 2.29
Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A (2003) 2.28
Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J Cell Biol (2002) 2.28
Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science (2002) 2.28
TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol (2012) 2.24
The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol (2002) 2.22
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21
Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol (2003) 2.20
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A (2003) 2.20
The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol (2010) 2.18
Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell (2007) 2.18
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell (2011) 2.17
Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J (2002) 2.13
Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem (2004) 2.13
Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) (2013) 2.12
Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature (2008) 2.09
Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation (2005) 2.09
Identification of signaling pathways regulating primary cilium length and flow-mediated adaptation. Curr Biol (2010) 2.08
Increased expression of the collagen receptor discoidin domain receptor 2 in articular cartilage as a key event in the pathogenesis of osteoarthritis. Arthritis Rheum (2007) 2.07
The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol (2010) 2.03
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
BMP-7 functions as a novel hormone to facilitate liver regeneration. FASEB J (2006) 2.02
Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology (2003) 1.97
Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes (2007) 1.94
Determinants of vascular permeability in the kidney glomerulus. J Biol Chem (2002) 1.93
Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem (2014) 1.92
Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res (2005) 1.92
The genetic basis for skeletal diseases. Nature (2003) 1.92
Stem cell therapies benefit Alport syndrome. J Am Soc Nephrol (2009) 1.83
NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest (2002) 1.81
Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol (2007) 1.79
Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem (2005) 1.79
Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta (2005) 1.76
Origins of cardiac fibroblasts. Circ Res (2010) 1.76
Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair. Curr Top Dev Biol (2005) 1.75
Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol (2012) 1.70
Mice deficient in alpha-actinin-4 have severe glomerular disease. J Clin Invest (2003) 1.69
Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med (2012) 1.68